Conflict of interest.Acknowledgements. This perform was supported by the Swedish Health-related ?Study Council (VR), the Swedish Cancer Society, Cancerforeningen and Karolinska Institutet.1. Hussain SP, Harris CC. P53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 1999; 428: 23?two. 2. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Influence of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from current developments in the IARC TP53 database. Hum Mut 2007; 28: 622?29. 3. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303?12. 4. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157?165. five. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of distinct p53 mutants on resistance of cultured cells to chemotherapy.Tris(pyrazol-1-yl)methane custom synthesis Oncogene 1999; 18: 477?85. 6. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661?65. 7. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656?60. eight. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323?334.Targeting of TrxR1 by APR-246/PRIMA-1MET X Peng et al9. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286: 2507?510. 10. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration from the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; eight: 282?88. 11. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent development suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information and facts inside the National Cancer Institute database.Pd 122 Chemscene Carcinogenesis 2002; 23: 2011?018.PMID:23398362 12. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005; 24: 3484?491. 13. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005; 280: 30384?0391. 14. Zache N, Lambert JM, Rokaeus N, Shen J, Hainaut P, Bergman J et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2008; 2: 70?0. 15. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008; 105: 10360?0365. 16. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell 2012; 21: 614?25. 17. Zache N, Lambert JM, Wiman KG, Bykov VJ. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 2008; 30: 411?18. 18. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT. PRIMA-1(MET)/ APR-246 targets mutant types of p53 household members p63 and p73. Oncogene 2010; 29: 6442?451. 19. Shen J, van den Bogaard EH, Kouwenhoven EN, B.